Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is a clinical-stage biotech company with a focus on developing novel therapeutics in severe eye diseases and other organs through the Wnt signaling pathway. With its lead candidate SZN-8141, Surrozen is targeting improved efficacy, longer-lasting results, and reduced injection frequency compared to current retinal therapies, which is a critical factor for potential differentiation and adoption in retinal vascular diseases. With positive preclinical results and a strong pipeline, along with a partnership with Boehringer Ingelheim, Surrozen is well-positioned for potential success in the competitive retinal disease space.

Bears say

Surrozen is a clinical-stage biotechnology company that has demonstrated promising preclinical results with its product candidate, SZN-8141, in terms of accelerating vascular regeneration and reducing avascular and pathological neovascular tuft areas in retinal vascular disease. However, the company reported a net loss of $127.5M for 1Q26 and will require substantial financing for development and commercialization. Additionally, there are still questions about the durability and long-term effectiveness of novel therapies in the retinal therapeutic space.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.